Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
Zhenyu Lin, Ming Cai, Peng Zhang...
https://pubmed.ncbi.nlm.nih.gov/34725214/Actively Recruiting
Led by brenner baruch · Updated on 2025-07-24
134
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating the addition of immunotherapy with tislelizumab to the current most effective treatment approach for locally advanced rectal cancer LARC. This phase II randomized controlled trial aims to assess whether combining tislelizumab with total neoadjuvant therapy TNT can improve long-term, surgery-free survival over standard TNT alone. The study focuses on new treatment combinations designed to enhance the immune response and potentially reduce the need for major surgery called total mesorectal excision TME. Participants will be randomly assigned to one of two groups. The experimental group receives 6 weeks of capecitabine-based chemoradiotherapy CRT, followed by 16 weeks of chemoimmunotherapy with tislelizumab and mFOLFOX6 chemotherapy every two weeks. The control group receives the same CRT followed by 16 weeks of mFOLFOX6 chemotherapy alone, also every two weeks. After treatment, patients will be evaluated around 8 weeks later to check tumor response and decide further management, including close monitoring or surgery if needed. Throughout the study, participants will undergo regular assessments including imaging and clinical exams to monitor tumor status and side effects. Researchers will track outcomes such as 3-year surgery-free survival, disease-free survival, overall survival, and safety events. Follow-up will continue according to standard guidelines to observe long-term effects. The total participation time spans multiple years to capture these outcomes and ensure careful monitoring of health and treatment effects.
CONDITIONS
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
B
Baruch Brenner, M.D
A
Ayelet Rosenberg Ayal, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
brenner baruch
Lead Sponsor
Johannes Gutenberg University Mainz
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 26 weeks
Participants receive 6 weeks of capecitabine-based chemoradiotherapy followed by 4 weeks without treatment, then 16 weeks of chemotherapy every 2 weeks. Participants in the experimental arm also receive immunotherapy with tislelizumab during chemotherapy.
Multiple visits every 2 weeks during chemotherapy phases
Duration - Up to 36 months or longer
Participants are re-staged around 8 weeks after completion of treatment and undergo surgery if needed. They are then followed according to current clinical guidelines to monitor health and outcomes.
Follow-up visits according to guidelines, including re-staging visit around 8 weeks post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Zhenyu Lin, Ming Cai, Peng Zhang...
https://pubmed.ncbi.nlm.nih.gov/34725214/Andrea Cercek, Campbell S D Roxburgh, Paul Strombom...
https://pubmed.ncbi.nlm.nih.gov/29566109/I D Nagtegaal, C A Marijnen, E K Kranenbarg...
https://pubmed.ncbi.nlm.nih.gov/11481031/Silvia C Formenti, Sandra Demaria
https://pubmed.ncbi.nlm.nih.gov/19573801/Laurence Zitvogel, Lionel Apetoh, François Ghiringhelli...
https://pubmed.ncbi.nlm.nih.gov/18097448/Laurence Bernier, Svetlana Balyasnikova, Diana Tait...
https://pubmed.ncbi.nlm.nih.gov/29576755/Xi Zhong, Zhonghua Wu, Peng Gao...
https://pubmed.ncbi.nlm.nih.gov/29464874/Loise M Francisco, Peter T Sage, Arlene H Sharpe
https://pubmed.ncbi.nlm.nih.gov/20636820/Julio Garcia-Aguilar, Oliver S Chow, David D Smith...
https://pubmed.ncbi.nlm.nih.gov/26187751/Rebecca L Siegel, Angela N Giaquinto, Ahmedin Jemal
https://pubmed.ncbi.nlm.nih.gov/38230766/brenner baruch
Lead Sponsor
Johannes Gutenberg University Mainz
Collaborating Sponsor